We investigated the concentration of soluble CD4 molecules (sCD4) in serum, and the mechanism of sCD4 production from T lymphocytes, in patients with rheumatoid arthritis (RA). The concentration of sCD4 molecules was determined using a solidphase enzyme-linked immunosorbent assay method. Using reverse transcription polymerase chain reaction (RT-PCR) techniques, we studied the presence of alternatively spliced mRNA encoding the transmembrane site of CD4, and the mRNA encoding a conservative region of the CD4 binding site of the human immunodeficiency virus (HIV), in the serum of RA patients. Levels of sCD4 found in RA patients were higher than in normal controls (199 U/ml compared with 8.4 U/ml, respectively), and correlated with additional medical parameters. The results of RT-PCR suggested that the higher sCD4 levels may be due to shedding from the cell membrane after protease digestion, not to alternative splicing or a reaction to viral binding to sCD4.
Introduction
The CD4 molecules are members of the immunoglobulin gene superfamily that exist in functionally distinct sub-populations of T lymphocytes. Initially, the CD4 molecules were thought to be phenotypic markers, with CD4-positive T-lymphocytes being helper cells and CD8 T-lymphocytes being suppressor cells. 1, 2 It is now widely recognized, however, that CD4 is only weakly associated with T-lymphocyte function. 3 The CD4 molecules are in fact strongly associated with the major histocompatibility complex (MHC) restriction, i.e. they appear to be involved in enhancing the avidity and/or affinity of cell-cell interactions. This is mediated by direct binding to the determinants of the MHC antigens on target cells such as B lymphocytes and antigenpresenting cells. 4 In addition, CD4 molecules act as receptors for class II MHC and the human immunodeficiency virus (HIV). 5 They may also deliver regulatory signals to immunologically competent cells in vivo. 6 Increased Soluble CD4 Molecules and the Role of Soluble CD4 Production in Patients with Rheumatoid Arthritis T Ohkubo, M Takei, K Mitamura et al.
Soluble CD4 in rheumatoid arthritis patients
The CD4 molecule is a 55-kD glycoprotein that has four extracellular domains. The most distal membrane domain displays homology with immunoglobulin light chain variable sequences. 7 These CD4 molecules can be membrane-bound or, in truncated form, free in serum, 8 and elevated levels of the truncated soluble form of CD4 (sCD4) have been reported in patients with several diseases and HIV-positive individuals. 8 -17 Rheumatoid arthritis (RA) is characterized by immunocompetent cell infiltration into the synovial tissue, and immunohistological analysis of lymphocytes in inflamed joint synovium has demonstrated that the majority of infiltrating cells are CD4-positive T-lymphocytes. 18 Previous studies reporting on sCD4 expression in RA have produced conflicting results. 17, 19, 20 High sCD4 levels have been observed in patients with active RA in some studies; 17, 19 others indicated serum sCD4 levels in RA patients to be similar to levels in controls. 20 Little is known about the mechanism of sCD4 production in RA patients. Possible methods include shedding from cell membranes by proteolysis, alternative exon splicing, or separation from the glycosylphosphatidyl anchor. 7 The increased number of sCD4 molecules observed in HIVinfected subjects may be due to a feedback mechanism for the inhibition of HIV replication. 8, 9 Several investigators have demonstrated an association between some viral infections and the pathogenesis of RA, 21 -25 and an unknown virus, with a binding site on sCD4 similar to HIV, may be involved in RA. In this study, therefore, we measured sCD4 concentration in sera from patients with RA, including those with disease stages II -IV, and studied the possible mechanisms of sCD4 production in those patients with RA who had high concentrations of sCD4.
Patients and methods
For this study, we obtained informed consent from each patient or healthy control and followed the Helsinki Declaration (Hong Kong Amendment, September 1989).
PATIENTS
Patients with RA disease stages II -IV diagnosed using American College of Rheumatology (ACR) criteria, 26 and osteoarthritis (OA) patients who fulfilled ACR diagnostic criteria, 27, 28 were eligible for inclusion in the study. Patients with clinically apparent infections of recent onset and concomitant illnesses involving other collagen-related diseases were excluded. Healthy volunteers acted as control subjects, matched to the RA patients by age and sex.
ASSAY FOR CONCENTRATION OF sCD4 MOLECULES
Sera was obtained from RA patients and normal controls: blood was taken into dry glass tubes and sera were frozen at -80 ºC and stored at this temperature until use. The concentration of sCD4 was determined using a solid-phase enzyme-linked immunosorbent assay (ELISA; Cell Free CD4 Bead Assay Kit, T Cell Science Inc., Cambridge, MA, USA). Serum 50 µl, horseradish peroxidase-conjugated anti-human-CD4 antibody 150 µl, and anti-human-CD4 antibody-labelled beads 150 µl were added to a polystyrene test tube (Assist Co. Inc, Tokyo, Japan). Each tube was shaken to ensure mixing of the serum specimen with the reagents, and incubated further for 180 min at room temperature on a rotator set at 1500 rpm.
Unbound conjugate was removed by washing four times with phosphate-buffered saline. The antibody-coated beads were incubated with O-phenylenediamine 200 µl (in 7.5 mmol/l urea peroxide and thimerosal) and left for 30 min at room T Ohkubo, M Takei, K Mitamura et al. Soluble CD4 in rheumatoid arthritis patients temperature. Finally, 1 N sulphuric acid 1 ml was added to terminate the reaction, samples were removed into microtitres and the optimal density at 490 nm was measured by an ELISA analyser (model EPY 96, Toyo-Sokuki Co. Ltd, Tokyo, Japan). Serum concentration of sCD4 was determined by comparison with the standard curve according to the manufacturer's instructions: briefly, a standard curve was constructed from six standards by plotting concentration on the x axis versus absorbance on the y axis. Unknown values were determined from the resulting standard curve and expressed as units/ml. One unit of CD4 antigen is equivalent to 10 pg of recombinant sCD4. To calculate the concentration of sCD4 in the culture supernatant, the dose-responses of phytohaemagglutinin (PHA; Sigma, St Louis, USA) and lipopolysaccharide (LPS; Sigma) were examined. Peripheral blood lymphocytes were resuspended in serum-free RPMI-1640 (Sigma) containing penicillin (100 U/ml), streptomycin (100 µg/ml) and glutamine. The cells were then distributed in 200 µl aliquots in 96-well microtitre plates and were incubated at 37°C in 5% CO 2 /95% air for 24, 48 and 72 h with variable densities of PHA (0.5, 1.0, 1.5, 2.0, 5.0, 10.0 and 20.0 µg/ml) or LPS (1.0, 3.0, 5.0, 7.0 and 9.0 µg/ml), and non-stimulated.
CELLS
Peripheral blood lymphocytes from RA patients with high concentrations of sCD4 molecules in their serum compared to other patients studied were collected by specific gravity sedimentation using lymphocyte separation reagent (LSM; Organon Teknika Co., Durham, USA), according to the manufacturer's protocol. The T cells from peripheral blood were collected by passing the serum samples through a nylon-wool column. 29 Peripheral blood lymphocytes and T cells were also collected from healthy controls using these methods. As T-cell lines, TALL-104, CCRF-CEM, MOLT3, MOLT4, Jurkat and HUT were used (ATCC, Rockville, MD, USA) to analyse the mechanism of sCD4 production.
DETECTION OF MESSENGER RNA ENCODED CD4 TRANSMEMBRANE SITE IN PERIPHERAL BLOOD T CELLS AND T-CELL LINES
Each sample of T cells and T-cell lines was stimulated by anti-CD3 antibody (BD, Franklin Lakes, USA), phorbol myristate acetate (PMA; Sigma), PHA, LPS and interleukin 2 (IL-2; Sigma); unstimulated cells were used as controls. Total cellular RNA was extracted using the acid-guanidinium thiocyanate-phenol-chloroform extraction method. 30 Using a first-strand cDNA synthesis kit (Pharmacia, Uppsala, Sweden), cDNA was synthesized and amplified by polymerase chain reaction (PCR). The primers used were made for specific amplification of the section of CD4 genes encoding the transmembrane portion (forward-primer: 1180 -1203; reverseprimers: 1381 -1357, 1443 -1419; accession number: NM000616). 31
DETECTION OF POSSIBLE SOLUBLE CD4 VIRAL MESSENGER RNA BINDING SITES IN PERIPHERAL LYMPHOCYTES AND SYNOVIUM
To exclude the influence of the method for synthesis of cDNA for total RNA, reversetranscription was performed using both the oligo (dT) and random-hexamers methods. 32 Synovium samples were obtained from patients with RA and OA who underwent total joint replacement of knee or hip joints. The presence of possible viral binding sites of the cDNA was examined by PCR using primers for the CD4 HIV binding site, a conserved region which binds to the HIV envelope glycoprotein gp120 (forward-primer: 3) U/ml, P < 0.001, while eight patients with mutilans type RA had lower sCD4 levels (mean ± SD: 23 ± 23.6 U/ml). The amount of sCD4 in RA patients correlated with that of the erythrocyte sedimentation rate (ESR, mean ± SD: 49.5 ± 33.5 mm/h), the C reactive protein (CRP, mean ± SD: 2.1 ± 2.0 mg/dl), the rheumatoid factor (mean ± SD: 67 ± 54 titre) and sCD23 (mean ± SD: 13772 ± 20059 U/ml), while there was no correlation with other medical parameters, such as the serum concentration of sCD8, immunoglobulin, the titre of Epstein-Barr virus (EBV) associated nuclear antigen and the 2′,5′-oligoadenylate synthetase (2-5AS) (data not shown).
DETECTION OF ALTERNATIVE SPLICING OF CD4 MOLECULES IN RA PATIENTS BY PCR ANALYSIS
We confirmed the production of sCD4 from activated T cells in healthy individuals before analysing whether alternative splicing of CD4 occurred in RA patients. The highest concentration of sCD4 was 54.5 U/ml on day 2 of culture, and the concentration varied 7050-7069; reverse-primer: 7143-716; accession number: M15654). 33 -38 
STATISTICAL ANALYSIS
Non-parametric analysis was conducted using Wilcoxon's signed rank test. Correlations were established by Spearman's rank correlation co-efficient analysis. Analyses were conducted using the Statview™ 4.5 program (Macintosh).
Results
In total, 60 patients with RA were studied (age 52.5 ± 17.4 years; mean ± SD). They were all female, ranging in age from 31 to 72 years. Six OA patients were also included (age 58.3 ± 6.8 years; mean ± SD). The normal control subjects consisted of 50 ageand sex-matched individuals.
SERUM CONCENTRATION OF sCD4 MOLECULES
Serum concentrations of sCD4, calculated from patients with RA and healthy control subjects, are presented in Fig. 1 . Levels of sCD4 were found to be significantly increased in RA patients compared with controls (mean ± SD: The following showed mRNA bands of normal size: T-cell lines (Lanes 1 and 2: TALL-104; Lanes 3 and 4: HPB-ALL; Lanes 5 and 6: CCRF-CEM; Lanes 9 and 10: MOLT4; Lanes 11 and 12: Jurkat; Lanes 13 and 14: HUT 78, but not Lanes 7 and 8: MOLT3); T cells from healthy control subjects stimulated with mitogens (PHA or PMA) and anti-CD3 antibody; T cells from RA patients with high sCD4 concentrations. We had 
Discussion
In this study, levels of sCD4 in sera of female patients with RA were significantly higher than in normal controls. However, previous studies of the expression of sCD4 in RA have produced conflicting results. 20 Our results concur with those reported by others 17, 19 who have observed high levels of sCD4 in patients with active RA. The only reason why female patients with RA were selected for this study was because there were very few male patients with RA in our hospital.
In our study, the amount of sCD4 in patients with RA correlated with clinical parameters of inflammation, i.e. ESR and CRP. Increased levels of serum sCD4 have also been observed in patients with polymyalgia rheumatica, 10 polymyositis/ dermatomyositis, 11 Wegener's granulomatosis, 12 Behçet's disease, 13 acute Kawasaki disease, 14 infectious mononucleosis 15 and Sjögren's syndrome. 16 This seems to indicate that the release of sCD4 from the cell surface is a non-specific inflammatory response, and that greater inflammation induces higher levels of sCD4 in sera.
Soluble CD4 protein has been shown to inhibit HIV replication and syncytium formation selectively, but not class II-specific T-cell interactions. 8 The increased sCD4 levels observed in HIV-infected subjects 8 could be due to a feedback mechanism for the inhibition of HIV replication. 9 We hypothesize that high sCD4 levels in patients with RA suggest that an unknown viral infection, likely to be a retrovirus, is involved. Human T-cell lymphotropic virus type I (HTLV-I) pro-viral DNA has been detected in synovial fluid cells taken from articular lesions in patients with HTLV-I-associated chronic inflammatory arthropathy, 24 and HTLV-I has also been proposed as a risk factor for RA. 25 We have examined several possible mechanisms of sCD4-release from cell membranes, and the hypothesis that RA might be a retroviral infection. Previous studies report that alternative splicing is the mechanism of sCD8-release from cell membranes. 39, 40 The CD4 molecules have transmembrane sites, therefore this mechanism may also be applicable to sCD4 release. Using PCR in the present study, we did not detect a gene with deletion of the transmembrane region, suggesting that sCD4 release is not due to alternative splicing. Neither did we detect any retroviral mRNA encoding the conserved CD4 binding site of HIV gp120 in sera or synovium of RA patients. Thus, sCD4 production may not be due to a reaction to retroviral infection.
In this paper, we examined the role of sCD4 production in patients with RA. Our results show that high sCD4 concentrations in these patients are not due to alternative splicing or retroviral infection. We now speculate that sCD4 production may be due to shedding caused by cell activation.
